What FDA is requiring
On November 9, FDA directed application holders across the GLP-1 receptor agonist class to add a warning about the potential increased risk of nonarteritic anterior ischemic optic neuropathy, known as NAION, to the Warnings and Precautions section of their labels. The requirement includes semaglutide and tirzepatide products. FDA’s communication gave no common rollout date for the revised labels.1
How rare is the risk?
Across 126 randomized trials, FDA identified 15 probable cases. Ten occurred in GLP-1 treatment groups and five in comparison groups. The observed rates were 6.4 versus 3.8 cases per 100,000 person-years, an absolute difference of about 2.6 cases per 100,000 person-years of follow-up. These are pooled rates based on few events. They cannot estimate an individual patient’s risk or establish how risk varies among drugs in the class.1
FDA’s separate observational analysis of adults with type 2 diabetes found a higher rate of NAION among patients who started GLP-1 therapy than among those who started a DPP-4 inhibitor. The difference versus SGLT2 inhibitors was statistically inconclusive. Patient characteristics and the choice of comparison drug matter when interpreting these estimates.13
How the injury occurs
NAION occurs when reduced blood flow injures the front of the optic nerve. The nerve can swell after the initial injury. In a naturally crowded optic disc, swelling may further restrict circulation. This can lead to sudden, painless loss of some or all vision in one eye, sometimes permanently. Diabetes, high blood pressure, and obstructive sleep apnea are among the conditions associated with NAION.12
The injury mechanism does not establish how GLP-1 drugs might contribute. FDA’s review of animal data found no mechanism. Neuro-ophthalmology specialists have proposed that rapid improvement in blood glucose could contribute to optic disc swelling in susceptible patients. That remains a hypothesis.123
What pharmacists can do now
FDA advises patients to contact a healthcare professional immediately about sudden vision loss, new blind spots, or other sudden visual changes in one eye. Suspected NAION warrants prompt ophthalmology evaluation. If NAION develops, FDA advises clinicians to consider stopping the GLP-1 drug unless the benefits clearly outweigh the risk.1
For the pharmacy handoff, document when symptoms began, the affected eye, the current medication and dose, and who will arrange urgent evaluation. Treatment decisions after a confirmed event should account for the person’s eye history and the clinical benefits of the medication.12
What research would guide treatment by risk?
Larger studies with ophthalmologist-confirmed cases should compare individual drugs, doses, and indications while accounting for prior NAION, optic disc anatomy, and vascular risk. Follow-up after a confirmed event should examine outcomes when patients continue, stop, or switch treatment. Those studies could help determine which patients face a meaningful increase in risk and whether changing therapy lowers it.123
Source notes
- U.S. Food & Drug Admin., FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition (Nov. 9, 2026).
- Sarah W. DeParis et al., Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology, 133 Ophthalmology 1029, 1029, 1032–33 (2026).
- Cindy X. Cai et al., Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy, 143 JAMA Ophthalmology 304, 310–13 (2025).